Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 408841 - 408860 out of 563565 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Poland | (XXXXX04) medical devices | PIC Insupen Orginal 0,30x8 mm (30G), igły | 100 szt. | Retail price with vat |
$0-0 |
$0-0 |
n/a | n/a |
| Poland | (XXXXX04) medical devices | Suprasorb A, opatrunek z alginianu wapnia, sterylny, 10x10 cm, opatrunek, 100 cm² | 1 szt. | Retail price with vat |
$0-0 |
$0-0 |
n/a | n/a |
| Poland | (XXXXX04) medical devices | Suprasorb A, opatrunek z alginianu wapnia, sterylny, 10x20 cm, opatrunek, 200 cm² | 1 szt. | Retail price with vat |
$0-0 |
$0-0 |
n/a | n/a |
| Poland | (XXXXX06) veterinary medicines | Pazopanib Viatris, tabl. powl., 400 mg | 30 szt., 50 mg + 144 mg + 150 mg , 9 blistrów 2 tabl. | Wholesale price with vat |
$0-0 |
$0-0 |
n/a | ChanellePharmaceuticalsManufacturingLtd. |
| Poland | (A02BC05) esomeprazole (adm: O) | Emanera, kaps. dojel. twarde, 20 mg | 84 szt., 20 mg , 84 kaps. | Retail price with vat |
$0-0 |
$0-0 |
n/a | Krka,d.d.,Novomesto |
| Poland | (A02BC05) esomeprazole (adm: O) | Emanera, kaps. dojel. twarde, 40 mg | 84 szt., 40 mg , 84 kaps. | Retail price with vat |
$0-0 |
$0-0 |
n/a | Krka,d.d.,Novomesto |
| Poland | (A05AX05) odevixibat | Kayfanda, kaps. twarde, 1200 µg | 30 szt., 1200 mcg , 30 kaps. | Wholesale price with vat |
$0-0 |
$0-0 |
Pruritus;Alagille Syndrome | IpsenPharma |
| Poland | (A05AX05) odevixibat | Kayfanda, kaps. twarde, 200 µg | 30 szt., 200 mcg , 30 kaps. | Wholesale price with vat |
$0-0 |
$0-0 |
Pruritus;Alagille Syndrome | IpsenPharma |
| Poland | (A05AX05) odevixibat | Kayfanda, kaps. twarde, 400 µg | 30 szt., 400 mcg , 30 kaps. | Wholesale price with vat |
$0-0 |
$0-0 |
Pruritus;Alagille Syndrome | IpsenPharma |
| Poland | (A05AX05) odevixibat | Kayfanda, kaps. twarde, 600 µg | 30 szt., 600 mcg , 30 kaps. | Wholesale price with vat |
$0-0 |
$0-0 |
Pruritus;Alagille Syndrome | IpsenPharma |
| Poland | (A09AA02) multienzymes (lipase, protease etc.) | Lipancrea 16 000, kaps., 16000 j.Ph. Eur. lipazy | 60 szt., 16 000 j. Ph. Eur. lipazy , 60 kaps. | Retail price with vat |
$0-0 |
$0-0 |
n/a | ZakładyFarmaceutycznePOLPHARMAS.A. |
| Poland | (A10AE04) insulin glargine (adm: P) | Semglee, roztwór do wstrzykiwań we wstrzykiwaczu, 100 j./ml | 5 wstrzyk. po 3 ml, 100 j/ml , 5 wstrzyk. 3 ml | Retail price with vat |
$0-0 |
$0-0 |
Diabetes Mellitus | BiosimilarCollaborationsIrelandLtd |
| Poland | (A10BA02) metformin (adm: O) | Thinban, tabl. powl., 10 mg | 30 szt., 10 mg , 30 tabl. | Retail price with vat |
$0-0 |
$0-0 |
n/a | TEVAGmbH |
| Poland | (A10BA02) metformin (adm: O) | Thinban, tabl. powl., 15 mg | 30 szt., 15 mg , 30 tabl. | Retail price with vat |
$0-0 |
$0-0 |
n/a | TEVAGmbH |
| Poland | (A10BA02) metformin (adm: O) | Thinban, tabl. powl., 20 mg | 30 szt., 20 mg , 30 tabl. | Retail price with vat |
$0-0 |
$0-0 |
n/a | TEVAGmbH |
| Poland | (A10BB09) gliclazide (adm: O) | Diagen, tabl. o zmodyfikowanym uwalnianiu, 60 mg | 30 szt., 60 mg , 30 tabl. w butelce | Retail price with vat |
$0-0 |
$0-0 |
n/a | ViatrisLtd |
| Poland | (A10BD07) metformin and sitagliptin | Combodiab, tabl. powl., 50+1000 mg | 56 szt., 50 mg + 1000 mg , 56 tabl. | Retail price with vat |
$0-0 |
$0-0 |
n/a | BiotonS.A. |
| Poland | (A10BH01) sitagliptin (adm: O) | Sitagliptin Bioton, tabl. powl., 100 mg | 28 szt., 100 mg , 28 tabl. | Retail price with vat |
$0-0 |
$0-0 |
n/a | BiotonS.A. |
| Poland | (A10BK01) dapagliflozin (adm: O) | Daforbis, tabl. powl., 10 mg | 30 szt., 10 mg , 30 tabl. | Retail price with vat |
$0-0 |
$0-0 |
n/a | ViatrisLtd |
| Poland | (A10BK01) dapagliflozin (adm: O) | Dapazyna, tabl. powl., 10 mg | 28 szt., 10 mg , 28 tabl. | Retail price with vat |
$0-0 |
$0-0 |
n/a | PrzedsiębiorstwoProdukcjiFarmaceutycznejHASCO-LEKS.A. |
